What is Alpha Tau Medical Ltd (DRTS)?

Alpha Tau Medical Ltd (DRTS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of DRTS?

The current price of DRTS is $13.35. Prices are updated in real time on Stocks360.

What is DRTS's price-to-earnings (PE) ratio?

DRTS's trailing twelve-month PE ratio is -12.84, based on current price and earnings per share data available on Stocks360.

What is DRTS's market capitalization?

DRTS's market capitalization is $1,234,583,356.00, placing it in the small-cap tier.

Alpha Tau Medical Ltd (DRTS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$13.35

Market Cap

$1.23B

PE (TTM)

-12.84

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.22

Day Range

$13.31 – $13.63

52-wk Range

$3.43 – $15.79

Avg Volume

N/A

Volume

401.16K

Alpha Tau Medical Ltd (DRTS) is a publicly traded company in the Healthcare sector. Latest price: $13.35. Market cap $1.23B. Trailing PE -12.84. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 7 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $4.09 2026-10-28 · $13.35 (+226.41%)

Earnings

Most Recent

Aug 10, 2026

EPS $-0.50 vs est. $-0.14

Missed by $0.36

Next Earnings

Nov 19, 2026

EPS estimate $-0.14

Proprietary Signals

Signal snapshot temporarily unavailable.

About Alpha Tau Medical Ltd

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-12.84×
P/S (TTM)	0.00×
P/B	27.56×
PEG	0.18×
P/FCF (TTM)	-37.69×
EV / EBITDA	-25.00×
EV / Sales	0.00×
Earnings Yield	-7.62%
Free Cash Flow Yield	-2.65%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.23B
Net Income (TTM)	-$94.13M
Free Cash Flow (TTM)	$8.76M
Net Debt	-$7.84M
Working Capital	$97.20M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-138.12%
Return on Invested Capital	-40.04%